我們已在上線！進一步了解

Cytek Biosciences

CTKB

市值 US$6.82億

5.25 USD

-0.16

2.96%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

5.25

0.00

0%

1天

-2.96%

5天

-3.14%

1個月

6.49%

3個月

13.15%

6個月

13.88%

今年迄今

6.71%

1年

30.6%

5年

-77.75%

10年

-72.01%

關於： Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.

員工： 702

醫療保健醫療器材

新聞

正面

中性

負面

市場情緒 3個月

正面 7.1%

中性 78.6%

負面 14.3%

Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool

Cytek has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool to create the industry's first end-to-end flow cytometry platform.

Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool

Zacks Investment Research

Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?

Investors need to pay close attention to CTKB stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?

Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

FREMONT, Calif., and HAMBURG, Germany, Sept.

Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course.

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.

Cytek Biosciences to Participate in Upcoming Investor Conferences

Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding

FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in Cytek's favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents. The jury awarded past damages consisting of $20 million in lost profits and $36 million in royalties. Cytek intends to pursue post-verdict motions challenging the finding of infringement under the doctrine of equivalents and the related damages award.

Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding

Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript

Cytek Biosciences Q2 Earnings Call Highlights

Cytek Biosciences NASDAQ: CTKB reported second-quarter 2026 revenue growth of 6% year over year, supported by double-digit gains in the United States and China, while continued weakness in Europe and parts of Asia-Pacific limited overall growth.

Cytek Biosciences Q2 Earnings Call Highlights

Zacks Investment Research

Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.01 per share a year ago.

Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates

查看新聞排名

價格圖表採用Lightweight Charts™實作